[RHBBANK] YoY Quarter Result on 31-Dec-2018 [#4]

Stock
[RHBBANK] RHB BANK BERHAD
Announcement Date
27-Feb-2019
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2018
Quarter
31-Dec-2018 [#4]
Profit Trend
QoQ- -2.29%
YoY- 22.9%
Quarter Report
Latest QR
Upcoming QR
RHBBANK's Result
RHBBANK's Financial Summary
View:
Show?
Quarter Result
31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 CAGR
Revenue 2,891,784 3,081,021 3,424,937 3,309,713 2,702,271 2,557,553 2,818,305 0.42%
PBT 922,557 574,207 851,794 775,096 601,879 344,411 518,076 10.08%
Tax -291,296 -134,866 -229,017 -207,541 -139,775 -87,693 -152,947 11.32%
NP 631,261 439,341 622,777 567,555 462,104 256,718 365,129 9.54%
-
NP to SH 631,165 438,631 621,008 565,425 460,077 261,243 363,374 9.62%
-
Tax Rate 31.57% 23.49% 26.89% 26.78% 23.22% 25.46% 29.52% -
Total Cost 2,260,523 2,641,680 2,802,160 2,742,158 2,240,167 2,300,835 2,453,176 -1.35%
-
Net Worth 27,806,567 27,027,702 25,784,588 23,338,462 23,137,959 21,734,444 6,774,000 26.50%
Dividend
31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 CAGR
Div 1,028,638 707,772 741,858 521,305 401,004 280,703 433,801 15.46%
Div Payout % 162.97% 161.36% 119.46% 92.20% 87.16% 107.45% 119.38% -
Equity
31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 CAGR
Net Worth 27,806,567 27,027,702 25,784,588 23,338,462 23,137,959 21,734,444 6,774,000 26.50%
NOSH 4,142,918 4,010,045 4,010,045 4,010,045 4,010,045 4,010,045 2,656,470 7.68%
Ratio Analysis
31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 CAGR
NP Margin 21.83% 14.26% 18.18% 17.15% 17.10% 10.04% 12.96% -
ROE 2.27% 1.62% 2.41% 2.42% 1.99% 1.20% 5.36% -
Per Share
31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 CAGR
RPS 70.28 76.83 85.41 82.54 67.39 63.78 106.09 -6.62%
EPS 15.34 10.94 15.49 14.10 11.50 6.50 5.30 19.35%
DPS 25.00 17.65 18.50 13.00 10.00 7.00 16.33 7.34%
NAPS 6.7581 6.74 6.43 5.82 5.77 5.42 2.55 17.62%
Adjusted Per Share Value based on latest NOSH - 4,010,045
31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 CAGR
RPS 66.33 70.67 78.55 75.91 61.98 58.66 64.64 0.43%
EPS 14.48 10.06 14.24 12.97 10.55 5.99 8.33 9.64%
DPS 23.59 16.23 17.02 11.96 9.20 6.44 9.95 15.45%
NAPS 6.3777 6.1991 5.9139 5.3529 5.3069 4.985 1.5537 26.50%
Price Multiplier on Financial Quarter End Date
31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 CAGR
Date 31/12/21 31/12/20 31/12/19 31/12/18 29/12/17 30/12/16 31/12/15 -
Price 5.37 5.45 5.78 5.29 5.00 4.71 5.67 -
P/RPS 7.64 7.09 6.77 6.41 7.42 7.38 5.34 6.14%
P/EPS 35.01 49.82 37.32 37.52 43.58 72.30 41.45 -2.77%
EY 2.86 2.01 2.68 2.67 2.29 1.38 2.41 2.89%
DY 4.66 3.24 3.20 2.46 2.00 1.49 2.88 8.34%
P/NAPS 0.79 0.81 0.90 0.91 0.87 0.87 2.22 -15.80%
Price Multiplier on Announcement Date
31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 CAGR
Date 28/02/22 26/02/21 27/02/20 27/02/19 27/02/18 24/02/17 26/02/16 -
Price 5.80 5.42 5.60 5.59 5.47 4.93 5.35 -
P/RPS 8.25 7.05 6.56 6.77 8.12 7.73 5.04 8.55%
P/EPS 37.81 49.55 36.16 39.64 47.68 75.67 39.11 -0.56%
EY 2.64 2.02 2.77 2.52 2.10 1.32 2.56 0.51%
DY 4.31 3.26 3.30 2.33 1.83 1.42 3.05 5.92%
P/NAPS 0.86 0.80 0.87 0.96 0.95 0.91 2.10 -13.81%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment